Press Release – BLIS Technologies
From: BLIS Technologies Ltd (NZX:BLT) MediaPak: National Pak Date: Friday, 11 Dec 2013 Release: Immediate A new 2013 research report extends the benefit of BLIS K12 probioticFrom: BLIS Technologies Ltd (NZX:BLT)
MediaPak: National Pak
Date: Friday, 11 Dec 2013
A new 2013 research report extends the benefit of BLIS K12™ probiotic
BLIS Technologies Ltd (NZX:BLT) announces another clinical study, just published this month, which further supports the effectiveness of BLIS K12™ oral cavity probiotic for preventing ear and throat infections. Published in the medical science journal, Expert Opinion on Biological Therapy, an Italian research team demonstrated that they could prevent the reoccurrence of common ear and throat infections, such as strep throat infection and tonsillitis by more than 83% in adults. The study followed 40 adults with a history of recurrent ear and throat infection and examined the effect of 90 days of treatment with either the BLIS K12™ probiotic or a placebo. Researchers concluded “The regular use of BLIS K12 appears to have effected a substantial reduction in the incidence of recurrent oral streptococcal pathology, reducing the requirement for these BLIS K12-treated individuals to be exposed to therapeutic courses of antibiotics.”
Di Pierro, F., et al. (2013). Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opinion on Biological Therapy.
This paper has been published just two months after a similar research paper also concluded that regular use of BLIS K12 in children could reduce the incidence of strep throat infection (including tonsillitis) by more than 92%. The children examined in this earlier study, previously had a recurrence rate for strep throat infection of nearly 4 times per year, however those children who then were assigned to the treatment with the BLIS K12™ probiotic dropped dramatically their rate of infection to the equivalent of just one incidence, every 4 years.
BLIS Technologies CEO, Dr Barry Richardson said, “We have known from our own work over several years about the effectiveness of the BLIS K12™ probiotic in treating and preventing certain infections of the throat and upper airways but finally, we have an independent research group that has now corroborated these findings. It is reassuring to us to know that BLIS K12™ has been independently supported as being highly efficacious in both children and adults.”
Dr Richardson said that he has seen a growing awareness among healthcare professional in New Zealand, pharmacists, dentist and doctors of benefits of BLIS K12™ probiotic for mouth and throat and has seen an increasing acceptance to consider BLIS K12™ probiotic as an option when managing the health of their patients, both young and old.